Penetrating Keratoplasty (Full-Thickness Corneal Transplant): Procedure, Outcomes and Alternatives — Cost, Top Hospitals & Success Rates | MyMedicPlus

Penetrating keratoplasty (PK), also called full-thickness corneal transplantation or perforating keratoplasty, is a surgical procedure in which the entire diseased or injured cornea — from epithelium to endothelium — is excised and replaced with a full-thickness button of donor corneal tissue. It is one of the most commonly performed and most successful solid-tissue transplants in human medicine, with approximately 185,000 procedures performed globally each year.

The term "optical" keratoplasty distinguishes the procedure from tectonic keratoplasty (performed to restore structural integrity without a primary visual goal) and therapeutic keratoplasty (to remove infected or ulcerated tissue). Optical PK aims to restore corneal clarity and regularity to improve visual acuity in patients whose vision is compromised by irreversible corneal disease.

The operative technique involves trephination — using a circular cutting instrument (trephine) of 7.5–8.5 mm diameter — to excise a disc of the recipient's diseased cornea and replace it with a size-matched or 0.25 mm larger donor button. The graft is secured with 16 interrupted or one running 10-0 nylon suture (or a combined technique), and the anterior chamber is reformed with balanced salt solution or viscoelastic.

Donor tissue is sourced from eye banks, which evaluate donor corneas for endothelial cell density, clarity, and infectious disease screening. The endothelial cell count is the most critical quality parameter: a count of >2,000 cells/mm² at the time of transplantation is the widely accepted minimum for a viable graft, as these non-regenerating cells are responsible for maintaining corneal deturgesence and transparency.

Long-term graft survival in the Australian Corneal Graft Registry (Williams et al.) demonstrates a 5-year survival of approximately 90% for Fuchs endothelial dystrophy — the most favourable indication — and 70% for keratoconus, with declining rates for regraft and vascularised host beds.

Penetrating keratoplasty is indicated for a broad range of corneal diseases causing visual disability that cannot be corrected with spectacles, contact lenses, or corneal surface treatments:

• Fuchs endothelial corneal dystrophy: The most common indication in the Western world. Progressive loss of corneal endothelial cells leads to stromal oedema, epithelial bullae, and reduced visual acuity. PK historically was the treatment of choice, though DSAEK and DMEK have now largely replaced PK for Fuchs dystrophy in high-resource settings.
• Keratoconus: Progressive ectatic corneal thinning and steepening causes irregular astigmatism unmanageable with spectacles or contact lenses. PK is indicated for advanced keratoconus (hydrops, extreme ectasia, or contact lens intolerance). DALK is now preferred when endothelial function is preserved.
• Corneal scarring: Post-infective scars from bacterial keratitis, herpes simplex virus (HSV) keratitis, fungal keratitis, or trachoma; post-traumatic scarring; and chemical or thermal burn-related scarring affecting the visual axis.
• Bullous keratopathy: Pseudophakic or aphakic bullous keratopathy arising from intraocular lens-related endothelial damage following cataract surgery. DSAEK or DMEK are increasingly preferred for isolated endothelial disease without stromal scarring.
• Corneal ulceration refractory to medical therapy: Severe microbial keratitis (bacterial, fungal, or Acanthamoeba) threatening corneal perforation or resistant to antimicrobial therapy may require therapeutic keratoplasty, which simultaneously addresses the structural compromise and the infectious aetiology.
• Corneal dystrophies: Macular, granular, lattice, and congenital hereditary stromal or endothelial dystrophies affecting the visual axis and unresponsive to superficial corneal procedures.
• Regraft: Repeat keratoplasty for primary graft failure, irreversible graft rejection, or late endothelial failure after a previous PK or lamellar procedure.

Eligibility for penetrating keratoplasty is assessed by an experienced corneal surgeon, weighing visual potential, systemic health, ocular surface conditions, and the availability of suitable donor tissue:

• Reduced visual acuity attributed to corneal disease: PK is indicated when corneal opacity, oedema, or irregularity is the primary cause of visual impairment and correction by optical means (spectacles, rigid contact lenses) is not achieving functional vision. Best-corrected visual acuity (BCVA) below 6/18 attributable to the cornea is a general threshold.
• Reasonable visual potential: The patient must have adequate retinal and optic nerve function to benefit from corneal clarity restoration. Pre-operative low-contrast visual assessment, electrodiagnostics, or B-scan ultrasound is used to exclude posterior segment disease that would limit visual recovery.
• Stable systemic and ocular surface status: Active anterior segment inflammation, uncontrolled glaucoma, dry eye disease requiring aggressive management, or lid abnormalities (lagophthalmos, entropion, trichiasis) must be identified and addressed before keratoplasty to avoid early graft failure.
• Adequate donor tissue availability: Donor corneas must meet the eye bank's quality thresholds: endothelial cell density >2,000 cells/mm², central corneal clarity, absence of opacities, and negative serological screening for HIV, hepatitis B and C, syphilis, and other transmissible infections per regional regulatory standards.
• Absence of high-risk factors for rejection: Corneal neovascularisation (two or more quadrants), prior ipsilateral graft failure, and limbal stem cell deficiency substantially increase rejection risk and may require additional interventions (limbal stem cell transplantation, immunosuppressive management) before or during keratoplasty.
• Informed consent: The patient must understand the need for topical immunosuppression (corticosteroids) for at least 12–24 months, the risk of rejection (approximately 20% within 5 years), the prolonged visual rehabilitation (12–18 months for full refractive stability), and the lifelong need for eye protection.

The choice among corneal transplantation techniques depends on which layers of the cornea are diseased, whether the endothelium is functional, and the extent of pathological involvement:

• Penetrating keratoplasty (full-thickness): Replaces all five layers of the cornea. Indicated when disease involves multiple layers (stroma and endothelium), when pathology cannot be excised by lamellar techniques, or when the host bed is vascularised or scarred to a degree that precludes successful lamellar dissection. Trephine sizes of 7.5–8.5 mm are standard; oversizing the donor button by 0.25 mm (donor larger than recipient) maintains normal anterior chamber depth and tension. Suture options include 16 interrupted sutures (allows selective removal of tight sutures to reduce post-operative astigmatism), a single running 10-0 nylon, or a combined approach.
• Deep anterior lamellar keratoplasty (DALK): Replaces the corneal stroma and epithelium while preserving the recipient's own Descemet membrane and endothelium. Ideal for keratoconus, stromal scarring, and stromal dystrophies with a healthy endothelial layer. Big-bubble technique (Anwar) uses air injection to separate Descemet membrane from stroma. Avoids endothelial rejection risk and achieves comparable visual outcomes to PK for keratoconus at experienced centres.
• Descemet stripping automated endothelial keratoplasty (DSAEK): Replaces the diseased endothelium and Descemet membrane using a donor lenticule 100–200 microns thick that also includes a thin layer of posterior stroma. Performed through a 5 mm scleral incision. Less technically demanding than DMEK; provides faster visual recovery than PK. Widely used for Fuchs dystrophy and bullous keratopathy.
• Descemet membrane endothelial keratoplasty (DMEK): Replaces only the diseased Descemet membrane and endothelial monolayer with an ultra-thin donor graft (10–15 microns). Provides the fastest and best visual outcomes (logMAR 0.0–0.1) with the lowest rejection rate of all endothelial keratoplasty techniques. Technically demanding; requires specialised donor preparation and injection systems.
• Paton speculum: A specialised lid speculum commonly used during PK to provide broad exposure and facilitate the trephination and suturing steps, particularly in patients with small or deep-set orbits.

Penetrating keratoplasty offers transformative visual rehabilitation for patients with significant corneal disease, with several well-documented clinical benefits:

• Significant visual improvement: The majority of patients with Fuchs dystrophy or keratoconus achieve best-corrected visual acuity of 6/12 or better after full visual rehabilitation (12–18 months post-operatively). Studies consistently demonstrate mean improvement of 4–6 Snellen lines in appropriately selected patients.
• High graft survival rates: The Australian Corneal Graft Registry reports 5-year graft survival of approximately 90% for Fuchs dystrophy and around 70% for keratoconus. Survival is substantially lower for regraft (50% at 5 years) and in vascularised host beds.
• Restoration of pain-free vision: Patients with bullous keratopathy suffer from recurrent painful epithelial blistering; PK resolves this by replacing the diseased endothelium with healthy donor tissue that restores corneal deturgesence and eliminates bullae formation.
• Versatility across diseases: Unlike selective lamellar techniques, PK addresses combined stromal and endothelial pathology in a single procedure, making it the most broadly applicable corneal transplant technique.
• Long-established safety and outcome record: PK has been performed since Zirm's first successful human corneal transplant in 1905, with over 100 years of accumulated technique refinement, suture material evolution, and post-operative immunosuppression optimisation.
• Reversibility through regraft: Unlike many surgical procedures, keratoplasty failure can in most cases be addressed by repeat transplantation, providing a second or even third opportunity for visual rehabilitation, though with progressively declining success rates.

Penetrating keratoplasty carries both early and late complications that must be fully disclosed during pre-operative counselling:

• Graft rejection: The most important long-term complication. The immune system mounts T-cell-mediated rejection against donor HLA antigens, manifesting as keratic precipitates (KPS) on the donor endothelium, anterior chamber cellular reaction, stromal oedema, and vascular ingrowth. Rejection episodes must be recognised immediately and treated aggressively with hourly topical prednisolone 1% and, in severe cases, systemic corticosteroids or tacrolimus. Approximately 20% of PK recipients experience at least one rejection episode within 5 years; most are reversible if treated promptly.
• Primary graft failure: Immediate post-operative graft failure without antecedent rejection, typically due to inadequate donor endothelial reserve, trauma during surgery, or pre-existing donor corneal disease not identified at eye bank assessment. Incidence is <1–2% with contemporary eye bank standards.
• Post-operative astigmatism: Surgically induced astigmatism averages 3–4 dioptres after PK but can exceed 10 dioptres in some cases. Management includes selective suture removal (to flatten steep meridians), rigid gas-permeable contact lenses, and, after full suture removal and refractive stability, astigmatic keratotomy, photorefractive keratectomy (PRK), or toric IOL implantation.
• Elevated intraocular pressure (steroid-response glaucoma): Prolonged topical corticosteroid use post-operatively induces clinically significant IOP elevation in 20–30% of patients. Regular IOP monitoring and anti-glaucoma therapy are essential throughout the post-operative period.
• Wound dehiscence: Anterior segment surgery creates a weak wound; even minor ocular trauma can cause catastrophic wound dehiscence (rupture at the graft-host junction) months to years after PK. Patients should wear protective eyewear permanently.
• Infectious keratitis: Bacterial, fungal, or viral keratitis at the graft-host junction or within the donor tissue can threaten graft survival and requires urgent microbiological investigation and targeted therapy.
• Suture-related complications: Broken, loose, or exposed 10-0 nylon sutures act as a focus for microbial colonisation and vascularisation; regular slit-lamp review for suture integrity and selective suture removal are essential throughout the post-operative period.

Post-operative care after penetrating keratoplasty is intensive and prolonged, typically spanning 2–3 years or longer for suture management and refractive stabilisation:

• Immediate post-operative period (day 1 to week 4): Hourly topical antibiotic drops (ofloxacin or moxifloxacin) for 2–4 weeks to prevent infection. Topical prednisolone 1% four to six times daily for anti-rejection prophylaxis. Cyclopentolate 1% for cycloplegia and anterior chamber quiescence. First-day review assesses graft clarity, anterior chamber depth, and IOP.
• Topical corticosteroid tapering (weeks 4 to 52): Prednisolone is slowly tapered over 12–24 months, based on graft clarity, cellular activity, and rejection risk profile. Many corneal surgeons maintain low-dose topical corticosteroid indefinitely in high-risk cases.
• Suture management: Interrupted sutures are selectively removed from tight meridians (identified by corneal topography) beginning at 6–12 months to reduce post-operative astigmatism. Running sutures are generally removed at 18–24 months. Each suture removal session requires a slit-lamp examination and may be followed by significant refractive change.
• Intraocular pressure monitoring: IOP is checked at every clinic visit given the risk of steroid-response glaucoma. Anti-glaucoma drops or systemic carbonic anhydrase inhibitors are added as needed, with threshold for glaucoma surgery in the context of keratoplasty carrying additional risk.
• Rejection episode recognition (Khodadoust sign / KPS): Patients are educated to recognise rejection symptoms — sudden decrease in vision, photophobia, redness, and pain — and to attend immediately for slit-lamp examination. Keratic precipitates on the donor endothelium (Khodadoust line) are pathognomonic of endothelial rejection.
• Refraction and contact lens fitting: Final spectacle or rigid gas-permeable contact lens prescription is possible only after all sutures are removed and refractive stability is achieved — typically 18–24 months post-operatively. Toric rigid lenses are highly effective for residual irregular astigmatism after PK.

The cost of penetrating keratoplasty encompasses surgical fees, donor tissue procurement, post-operative medications, and long-term surveillance. Key cost determinants include:

• Donor corneal tissue: Eye bank processing, endothelial cell counting, serology testing, and storage cost USD 1,500–4,000 per donor button in high-income countries. In India and other countries with public eye banking, tissue may be available at little or no cost to the patient through the hospital.
• Surgical and anaesthesia fees: PK performed by an experienced corneal surgeon at a tertiary eye hospital typically costs USD 2,000–6,000 in India, Thailand, or Eastern Europe, versus USD 8,000–20,000 in the United States or Western Europe, exclusive of facility and anaesthesia charges.
• Hospital and operating facility fees: Day-case or overnight stay procedures at accredited ophthalmic surgical centres add USD 1,000–5,000 in most countries. Complex cases with concurrent glaucoma surgery or IOL exchange require longer theatre time and higher facility costs.
• Post-operative medications: Prolonged topical corticosteroid, antibiotic, and lubricant therapy costs USD 50–200 per month for 12–24 months. In countries without drug price regulation, branded corticosteroid eye drops can cost significantly more.
• Rigid gas-permeable contact lenses: Many PK recipients require custom-fitted RGP lenses to achieve best visual acuity, costing USD 300–1,200 per pair with annual replacement.
• Lifetime surveillance: Annual slit-lamp examinations, corneal topography, IOP measurement, and graft integrity assessment represent ongoing costs of USD 200–800 per year depending on healthcare system and whether glaucoma management is required.

MyMedicPlus connects patients with accredited ophthalmic surgery centres across 48 countries, enabling cost comparisons and access to expert corneal surgeons at internationally competitive rates.

Modern corneal surgery has moved substantially toward selective lamellar techniques that replace only the diseased corneal layer, offering lower rejection rates, faster recovery, and better visual outcomes for specific indications compared to full-thickness PK:

• Deep anterior lamellar keratoplasty (DALK): The preferred alternative to PK for keratoconus, stromal dystrophies, and stromal scarring with a healthy host endothelium. DALK removes only the stroma (and epithelium) while preserving the patient's own Descemet membrane and endothelium, completely eliminating the risk of endothelial rejection. The big-bubble technique achieves a Descemet membrane plane cleavage in 60–80% of cases. Visual outcomes are equivalent to PK for keratoconus at experienced centres.
• Descemet stripping automated endothelial keratoplasty (DSAEK): Replaces the diseased endothelium and Descemet membrane with a posterior corneal lenticule (100–200 microns thick) inserted through a 5 mm incision. Indicated for Fuchs dystrophy and bullous keratopathy without significant stromal scarring. Provides faster visual rehabilitation (3–6 months) than PK, a more stable wound, and lower rejection rates. Best-corrected visual acuity of 6/12 or better is achieved in approximately 75–80% of patients.
• Descemet membrane endothelial keratoplasty (DMEK): Transplants an ultra-thin (10–15 microns) donor Descemet membrane plus endothelial monolayer without accompanying stroma. Provides the best visual outcomes of all corneal transplant techniques (logMAR 0.0–0.1 in 70–80% of patients), the lowest rejection rate (<1% per year), and the fastest recovery. Technically demanding; higher primary graft detachment rate requiring rebubbling than DSAEK.
• Collagen cross-linking (CXL): For keratoconus, riboflavin-UVA corneal cross-linking halts disease progression in the majority of treated eyes and may postpone or avert the need for keratoplasty. Not a visual rehabilitation treatment in itself, but a preventive strategy for patients with documented progression.
• Scleral contact lenses: Large-diameter scleral lenses vault the entire cornea, providing excellent vision for irregular astigmatism from keratoconus, post-keratoplasty astigmatism, or corneal scarring without surgery. A non-surgical alternative for patients with mild to moderate disease or those unwilling or unsuitable for surgery.
• Artificial cornea (keratoprosthesis): The Boston keratoprosthesis (KPro) is reserved for patients who have failed multiple PK grafts or have conditions incompatible with conventional corneal transplantation (severe limbal stem cell deficiency, severe dry eye, end-stage chemical burns). It provides a synthetic optical cylinder surrounded by a donor corneal carrier.